Our results showed that treatment with statins not only reduced ETRA protein levels, but also prevented the downstream phosphorylation RAF/MEK/ERK cascade caused by ET-1, which was clearly activated in our model of NASH. The gene discussed is MAP2K7; the disease is metabolic dysfunction-associated steatohepatitis.